Clinical Trials on Psoriatic Erythroderma in Russian Federation

Total 115 results

Biocad

Active, not recruiting

Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis (PATERA)

Psoriatic Arthritis

Russian Federation, Belarus
National Medical Research Center for Children's...

Recruiting

Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

Congenital Ichthyosis

Russian Federation
National Medical Research Center for Children's...

Completed

Informative Value of Determining the Level of NF-κB Translocation in Lymphocyte Populations in Children With Psoriasis

Psoriasis Vulgaris

Russian Federation
LEO Pharma

Completed

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study (BODYGUARD)

Psoriasis Vulgaris

Russian Federation
Theramab LLC

Completed

TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

Psoriasis Vulgaris

Russian Federation
LEO Pharma

Completed

Body PSOriasis: Long-term Relapse CONTROL (PSO-CONTROL)

Psoriasis Vulgaris

Russian Federation
Biocad

Completed

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7)

Moderate to Severe Plaque Psoriasis

Russian Federation
AbbVie

Completed

A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation (Adherence)

Spondylarthritis | Psoriatic Arthritis | Ankylosing Spondylitis (AS)

Russian Federation
I.M. Sechenov First Moscow State Medical University

Recruiting

Cardiovascular Risk Predictors in Patients With Psoriasis

Cardiovascular Diseases | Psoriasis

Russian Federation
Novartis Pharmaceuticals

Completed

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement (MAXIMISE)

Axial Psoratic Arthritis

Belgium, Israel, Spain, Switzerland, Greece, Italy, Bulgaria, Germany, Hungary, Estonia, United Kingdom, Poland, France, Czechia, Russian Federation, Romania, Ireland, Finland
Biocad

Completed

International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Russian Federation
Biocad

Completed

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis (CALYPSO)

Psoriasis

Russian Federation
AbbVie (prior sponsor, Abbott)

Completed

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

Moderate to Severe Plaque Psoriasis

Russian Federation
Polichem S.A.

Completed

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis

Nail Psoriasis

Czechia, Russian Federation, Germany, Greece, Poland, Bulgaria, Latvia
Groupe Hospitalier Pitie-Salpetriere

Completed

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. (ReFlaP)

Psoriatic Arthritis

United States, Austria, Brazil, Canada, Estonia, France, Germany, Italy, Romania, Russian Federation, Singapore, Spain, Turkey, United Kingdom
Astellas Pharma Inc
Biogen

Completed

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Psoriatic Arthritis

Poland, Canada, United States, Russian Federation, Germany
Mabscale, LLC

Recruiting

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Plaque Psoriasis

Russian Federation
Mylan Inc.
Mylan GmbH

Completed

MYL-1401A Efficacy and Safety Comparability Study to Humira®

Psoriasis | Arthritis, Psoriatic

Bulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis (BE ACTIVE 2)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis (BE ACTIVE)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
Abbott
Almedis; Scientific Research Institute of Rheumatology, Moscow

Completed

Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Russian Federation
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

Poland, Australia, Czechia, Hungary, Serbia, Slovakia, Estonia, Spain, Russian Federation, Lithuania, Bulgaria
Amgen

Completed

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis (MOSAIC)

Psoriatic Arthritis

Spain, Belgium, Denmark, United States, Germany, Russian Federation, Austria, United Kingdom, Canada, Italy, Switzerland
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

Psoriatic Arthritis

United States, Germany, Spain, Poland, Romania, Canada, Russian Federation
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Juvenile Psoriatic Arthritis | Enthesitis Related Arthritis

South Africa, Italy, Belgium, Russian Federation, Turkey, Germany, Spain, United States, Poland
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
Novartis Pharmaceuticals

Recruiting

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (SPARROW)

Moderate-to-severe Plaque Psoriasis

Russian Federation
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Active Psoriatic Arthritis

Spain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

Psoriasis, Arthritic

United States, Spain, Russian Federation, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Ukraine, United Kingdom
AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
Sun Pharmaceutical Industries Limited

Completed

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Psoriatic Arthritis

United States, Argentina, Hungary, Mexico, Poland, Russian Federation, Spain, Ukraine
Novartis Pharmaceuticals

Completed

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

Juvenile Psoriatic Arthritis | Enthesitis-related Arthritis

South Africa, Italy, Belgium, Russian Federation, Turkey, Germany, United Kingdom, United States, Spain, Poland
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
Alvotech Swiss AG

Completed

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Poland, Georgia, Iceland, Russian Federation, Ukraine
Pfizer

Completed

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)

Psoriatic Arthritis

United States, Belgium, Spain, Taiwan, Australia, Brazil, Czechia, France, Germany, Mexico, Poland, Russian Federation, Slovakia, United Kingdom
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Amgen

Completed

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Psoriatic Arthritis

Spain, Canada, United States, Czechia, Russian Federation, Hungary, Australia, New Zealand, Estonia, Romania
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE COMPLETE)

Psoriatic Arthritis

United States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

Psoriatic Arthritis

United States, India, Greece, Thailand, Czechia, Philippines, Bulgaria, Russian Federation, Guatemala, South Africa, Malaysia, Colombia, Brazil, Poland, Turkey
Eli Lilly and Company

Completed

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)

Psoriatic Arthritis

Spain, Bulgaria, Czechia, Estonia, Mexico, Poland, Ukraine, United States, South Africa, Russian Federation, Slovakia, United Kingdom
Bausch Health Americas, Inc.

Completed

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-2)

Psoriatic Arthritis

United States, France, Hungary, Mexico, Poland, Germany, Canada, Greece, Russian Federation, Latvia
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
Pfizer

Completed

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (OPAL BROADEN)

Psoriatic Arthritis

United States, Canada, Spain, Germany, Australia, Hungary, Belgium, Mexico, Poland, Russian Federation, Taiwan, United Kingdom, Slovakia, Czechia, Bulgaria, France
Amgen

Completed

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE2)

Psoriatic Arthritis

United States, Italy, Belgium, France, Canada, Taiwan, United Kingdom, Czechia, Russian Federation, Hungary, Germany, Bulgaria, Estonia, South Africa, Poland, Spain
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia

Clinical Trials on Psoriatic Erythroderma in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations